Company logo

ACAD - ACADIA Pharmaceuticals Inc.

NASDAQ -> Healthcare -> Biotechnology
San Diego, United States

ACAD price evolution
ACAD
(in millions $) 31 Mar 2022 31 Dec 2021 30 Sep 2021 30 Jun 2021
Current assets
Cash $210.69 $153.21 $100.41 $272.73
Short term investments $241.06 $373.27 $445.65 $289.96
Net receivables $63.48 $65.34 $61.67 $51.82
Inventory $13.21 $14.1 $14.34 $10.79
Total current assets $542.22 $617.82 $640.92 $645.73
Long term investments
Property, plant & equipment $65.72 $66.31 $68.61 $70.57
Goodwill & intangible assets $0.37
Total noncurrent assets $82.03 $82.3 $76.76 $78.7
Total investments $241.06 $373.27 $445.65 $289.96
Total assets $624.25 $700.12 $717.67 $724.43
Current liabilities
Accounts payable $10.77 $6.88 $7.72 $9.06
Deferred revenue
Short long term debt
Total current liabilities $119.6 $96.07 $88.22 $95.33
Long term debt $55.48 $56.13 $57.68 $59.13
Total noncurrent liabilities $59.85 $63.16 $62.5 $64.26
Total debt $55.48 $56.13 $57.68 $59.13
Total liabilities $179.45 $159.23 $150.72 $159.59
Shareholders' equity
Retained earnings -$2266.63 -$2153.58 -$2110.48 -$2096.03
Other shareholder equity -$0.61 -$0.19 -$0 $0.04
Total shareholder equity $444.8 $540.89 $566.96 $564.84
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Current assets
Cash $153.21 $331.8 $194.47 $139.58
Short term investments $373.27 $305.93 $507.75 $338.76
Net receivables $65.34 $50.28 $37.87 $27.79
Inventory $14.1 $9.68 $6.34 $4.07
Total current assets $617.82 $717.62 $760.25 $526.11
Long term investments
Property, plant & equipment $66.31 $56.44 $12.7 $3.31
Goodwill & intangible assets $1.11 $2.58 $4.06
Total noncurrent assets $82.3 $65 $22.93 $14.1
Total investments $373.27 $305.93 $507.75 $338.76
Total assets $700.12 $782.62 $783.18 $540.2
Current liabilities
Accounts payable $6.88 $8.49 $7.22 $3.17
Deferred revenue
Short long term debt
Total current liabilities $96.07 $105.97 $74.83 $59.56
Long term debt $56.13 $44.46 $6.36
Total noncurrent liabilities $63.16 $49.64 $9.22 $1.56
Total debt $56.13 $44.46 $6.36
Total liabilities $159.23 $155.61 $84.05 $61.12
Shareholders' equity
Retained earnings -$2153.58 -$1985.71 -$1704.12 -$1468.86
Other shareholder equity -$0.19 $0.04 $0.3 -$0.37
Total shareholder equity $540.89 $627.01 $699.13 $479.08
(in millions $) 31 Mar 2022 31 Dec 2021 30 Sep 2021 30 Jun 2021
Revenue
Total revenue $115.47 $130.76 $131.61 $115.22
Cost of revenue $2.95 $2.44 $3.69 $2.53
Gross Profit $112.52 $128.31 $127.92 $112.69
Operating activities
Research & development $128.85 $66.94 $58.56 $56.94
Selling, general & administrative $96.68 $105.91 $81.67 $96.79
Total operating expenses $225.53 $172.97 $143.22 $156.4
Operating income -$113.02 -$44.66 -$15.3 -$43.71
Income from continuing operations
EBIT -$112.57 -$42.91 -$14.79 -$43.4
Income tax expense $0.48 $0.19 -$0.33 $0.47
Interest expense
Net income
Net income -$113.06 -$43.09 -$14.46 -$43.87
Income (for common shares) -$113.06 -$43.09 -$14.46 -$43.87
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Revenue
Total revenue $484.14 $441.75 $339.08 $223.81
Cost of revenue $10.84 $10.21 $11.34 $12.38
Gross Profit $473.3 $431.54 $327.73 $211.43
Operating activities
Research & development $239.41 $319.13 $240.38 $187.16
Selling, general & administrative $396.03 $388.66 $325.64 $265.76
Total operating expenses $643.74 $718.13 $574.28 $460.71
Operating income -$170.44 -$286.59 -$246.54 -$249.28
Income from continuing operations
EBIT -$167.52 -$280.97 -$234.38 -$243.94
Income tax expense $0.35 $0.61 $0.88 $1.26
Interest expense
Net income
Net income -$167.87 -$281.58 -$235.26 -$245.19
Income (for common shares) -$167.87 -$281.58 -$235.26 -$245.19
(in millions $) 31 Mar 2022 31 Dec 2021 30 Sep 2021 30 Jun 2021
Net income -$113.06 -$43.09 -$14.46 -$43.87
Operating activities
Depreciation $0.52 $0.54 $0.98 $0.93
Business acquisitions & disposals
Stock-based compensation $14.96 $12.88 $15.55 $22
Total cash flows from operations -$76.33 -$23.12 -$17.06 -$25.33
Investing activities
Capital expenditures -$0 -$0.04
Investments $131.34 $71.55 -$156.32 -$17.16
Total cash flows from investing $131.34 $71.55 -$156.32 -$17.21
Financing activities
Dividends paid
Sale and purchase of stock $2.47 $4.37 $1.07 $5
Net borrowings
Total cash flows from financing $2.47 $4.37 $1.07 $5
Effect of exchange rate $0 $0 $0 -$0
Change in cash and equivalents $57.48 $52.8 -$172.32 -$37.53
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net income -$167.87 -$281.58 -$235.26 -$245.19
Operating activities
Depreciation $3.34 $2.93 $2.77 $3
Business acquisitions & disposals
Stock-based compensation $63.62 $84.42 $82.27 $81.56
Total cash flows from operations -$125.66 -$136.17 -$151.13 -$167.47
Investing activities
Capital expenditures -$1.12 -$7.59 -$1.13 -$2.1
Investments -$69.98 $200.1 -$164.71 -$69.39
Total cash flows from investing -$71.1 $192.51 -$165.84 -$71.49
Financing activities
Dividends paid
Sale and purchase of stock $18.16 $81 $371.85 $306.65
Net borrowings
Total cash flows from financing $18.16 $81 $371.85 $306.65
Effect of exchange rate $0.01 -$0.01 $0 $0
Change in cash and equivalents -$178.59 $137.33 $54.88 $67.69
Fundamentals
Market cap $2.32B
Enterprise value $2.16B
Shares outstanding 161.38M
Revenue $493.06M
EBITDA -$210.70M
EBIT -$213.66M
Net Income -$214.48M
Revenue Q/Q 8.37%
Revenue Y/Y 7.60%
P/E ratio -10.81
EV/Sales 4.39
EV/EBITDA -10.27
EV/EBIT -10.13
P/S ratio 4.70
P/B ratio 5.21
Book/Share 2.76
Cash/Share 1.31
EPS -$1.33
ROA -31.01%
ROE -40.52%
Debt/Equity 0.29
Net debt/EBITDA 0.15
Current ratio 4.53
Quick ratio 4.42